Cagrilintide and Semaglutide Blend
Identity hold Research draft Appetite and blood sugar research No graded treatment evidence Identity hold: product contents not confirmed
Evidence design, not proof of benefit or product approval
Holds on this record
- Identity hold. The exact contents or formulation are not confirmed. It cannot be placed in an active plan.
- No supplier batch has been matched to this record. A reviewer must record batch evidence before approval.
- Not marked ready for client selection in the library.
- No human administration guide. Study routes are research descriptions, not instructions.
- Research draft. Not released customer guidance.
The nine headings
Each heading opens a plain summary, then the deeper evidence and the sources behind it.
What it is
The catalog names cagrilintide and semaglutide together. The amount of each and the final formulation are not verified.
Sources for this tile
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
The history
REDEFINE-1 tested trial coadministration. It did not validate this catalog's premixed vial.
Sources for this tile
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
How it works
No specific mechanism claim is cleared in this first record. A pathway, if later verified, still needs human outcomes before it can support a benefit claim.
What it helps
This product has an identity hold. Benefits cannot be assigned until the exact compound or formula is known.
Read this before you read a benefit into it
Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.
Human research found for this product
REDEFINE-1: cagrilintide with semaglutide A
| Proof grade | A |
|---|---|
| Design | Randomised controlled phase 3; related trial combination |
| People or model | Adults with overweight or obesity |
| Number | 3417 |
| Outcome measured | Weight |
| Result | A human trial of the named components was found. Its efficacy must not be assigned to an unverified supplier blend. |
| Route in the study | Subcutaneous |
| Duration | 68 weeks |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
The research
Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.
Sources for this tile
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
Overall state of the evidence
Status: identity-hold
Hold product claims until both amounts, identity and formulation are confirmed. Trial coadministration and one premixed vial are not interchangeable evidence.
Risk summary
Hold product claims until both amounts, identity and formulation are confirmed. Trial coadministration and one premixed vial are not interchangeable evidence.
What is still open
- Supplier identity and batch match have not been verified
- Full-text systematic review and complete interactions are not finished
- Both component amounts
- Compatibility and stability
- Actual label and batch evidence
Checks a reviewer must finish first
- Both component amounts
- Compatibility and stability
- Actual label and batch evidence
How to read the proof grades
- A: Controlled human trial. Note whether randomisation and blinding were confirmed.
- B: Small uncontrolled human study or chart review.
- C: Whole-animal intervention.
- D: Cell or other laboratory study.
- E: User reports. Kept separate and never substituted for a measured outcome.
- ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.
Go deeper
How to read the proof Open the checked detail
A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.
A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Open questions Open the checked detail
Supplier identity and batch match have not been verified
Full-text systematic review and complete interactions are not finished
Both component amounts
Compatibility and stability
Actual label and batch evidence
Research in people
Open the linked human study records. Each names the tested group, design, result and limits. Related-compound and non-treatment studies are marked so they cannot be used as product treatment proof.
Sources for this tile
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
Studies named in this tile
| Personal regimen | Not set. A study regimen is not a personal instruction. |
|---|
What people report
No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.
Each human record
REDEFINE-1: cagrilintide with semaglutide A
| Proof grade | A |
|---|---|
| Design | Randomised controlled phase 3; related trial combination |
| People or model | Adults with overweight or obesity |
| Number | 3417 |
| Outcome measured | Weight |
| Result | A human trial of the named components was found. Its efficacy must not be assigned to an unverified supplier blend. |
| Route in the study | Subcutaneous |
| Duration | 68 weeks |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
Why it is for you
This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
What you would notice
Hold product claims until both amounts, identity and formulation are confirmed. Trial coadministration and one premixed vial are not interchangeable evidence.
Sources for this tile
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
How it is taken
The related trial used injections under the skin. The supplier blend route is unverified. Research routes describe what was studied. They are not a client administration guide.
Sources for this tile
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
Routes seen in the research
- Subcutaneous
Dose and cycle fields in the library
These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.
| dose | Blank |
|---|---|
| unit | Blank |
| frequency | Blank |
| timeOfDay | Blank |
| foodTiming | Blank |
| route | Blank |
| injectionSite | Blank |
| cycleLength | Blank |
| restLength | Blank |
| titration | Blank |
| mixing | Blank |
| storage | Blank |
| expiryAfterMixing | Blank |
Identity
| What it is made of | The catalog names cagrilintide and semaglutide together. The amount of each and the final formulation are not verified. |
|---|---|
| Maker | Not recorded |
| Supplier batch matched | No. Not matched to a supplier batch. |
| Catalog sizes | 5mg to 10mg - Inherited reference only; stock and current product sizes unverified |
| Record checked on | 2026-10-08 |
Shared safety note
FDA flags immune reactions and impurities in several compounded peptides. Its notice also reports serious events in IV ipamorelin research, heart-rate and vessel-dilation reactions with CJC-1295, glucose concerns with GHRP-2/6, and serious case reports with melanotan II. Reports do not by themselves establish causation. This concerns proposed compounded products and routes, not every formulation worldwide.
Source
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)